`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`PAR PHARMACEUTICAL, INC.,
`
`Petitioner,
`
`V.
`
`NOVARTIS AG,
`
`Patent Owner.
`
`
`
`Case IPR2016—01479
`
`Patent No. 9,006,224
`
`
`DECLARATION IN SUPPORT OF PATENT OWNER NOVARTIS’S
`MOTION FOR PRO HAC VICE ADMISSION OF CHARLOTTE
`JACOBSEN UNDER 37 C.F.R. § 42.10
`
`NOVARTIS EXHIBIT 2037
`Par v Novartis, IPR 2016-01479
`Page 1 of5
`
`
`
`1.
`
`I, Charlotte Jacobsen, am more than twenty—one years of age, am
`
`competent to present this declaration, and have personal knowledge of the facts
`
`set forth herein.
`
`2.
`
`This declaration is given in support of Patent Owner Novartis’s
`
`Motion for Pro Hac Vice Admission.
`
`3.
`
`I am a partner at the law firm of Fitzpatrick, Cella, Harper &
`
`Scinto, in the f1rm’s New York office.
`
`4.
`
`I have been a patent litigation attorney for more than thirteen years.
`
`I have been litigating patent cases for this entire time period and have been
`
`involved in numerous cases involving patent validity and infringement, at both
`
`the District Court and the Federal Circuit.
`
`1 have extensive experience in bench
`
`trials.
`
`1 have also been involved in inter partes review proceedings before the
`
`Board. A significant portion of my work has involved biological and chemical
`
`arts, with particular emphasis on pharmaceuticals.
`
`I am, therefore, an
`
`experienced litigating attorney.
`
`5.
`
`I am a member in good standing of the State Bar of New York and
`
`the Bar of England and»Wales.
`
`I have never been suspended or disbarred from
`
`practice before any court or administrative body.
`
`NOVARTIS EXHIBIT 2037
`Par v Novartis, IPR 2016-01479
`Page 2 of 5
`
`
`
`6.
`
`No court or administrative body has ever denied my application for
`
`admission to practice before it.
`
`7.
`
`No court or administrative body has ever imposed sanctions or
`
`contempt citations on me.
`
`8.
`
`I have read and will comply with the Office Patent Trial Practice
`
`Guide and the Board’s Rules of Practice for Trials set forth in part 42 of 37
`
`C.F.R.
`
`9.
`
`I understand that I will be subject to the Off1ce’s Rules of
`
`Professional Conduct set forth in 37 C.F.R. §§ 11.101 et seq. and disciplinary
`
`jurisdiction under 37 C.F.R. § l1.l9(a).
`
`10.
`
`I have applied to appear pro hac vice in three (3) other proceedings
`
`before the Office in the last three (3) years. In Noven Pharm., Inc. v. Novartis
`
`AG et al., Inter Partes Reviews 2014-00549 and 2014-00550, and Par
`
`Pharmaceuticals, Inc. v. Novartis AG, Inter Partes Review 2016-00084, I
`
`sought and was granted permission to appear pro hac vice.
`
`11.
`
`I have an established familiarity with the subject matter at issue in
`
`this proceeding.
`
`I have been involved substantively in the instant matter and in
`
`District Court litigation involving the same patent.
`
`I have read in detail and
`
`NOVARTIS EXHIBIT 2037
`Par v Novartis. IPR 2016-01479
`Page 3 of 5
`
`
`
`understand the Petition filed by Petitioner and the challenged patent, U.S. Patent
`
`9,006,224 (“the ’224 patent”).
`
`I have also reviewed all the exhibits relied upon
`
`by Petitioner and Patent Owner in this proceeding, including each of the
`
`references cited in instituted Grounds 1-4.
`
`12.
`
`I have engaged in extensive strategic and substantive discussions
`
`regarding this proceeding with Nicholas N. Kallas, who is the lead counsel for
`
`Patent Owner in this proceeding and a registered practitioner (Reg. No. 31,530).
`
`I have also engaged in extensive substantive discussions with experts
`
`concerning issues relevant to this proceeding.
`
`13.
`
`Therefore, I have an established familiarity with the subject matter
`
`at issue in this proceeding.
`
`14.
`
`I declare further that all statements made herein of my own
`
`knowledge are true and that all statements made on information and belief are
`
`believed to be true and further that these statements were made with the
`
`knowledge that willful false statements and the like so made are punishable by
`
`fine or imprisonment, or both, under Section 1001 of Title 18 of the United
`
`States Code, and that such willful false statements may jeopardize the validity
`
`of the ’224 patent.
`
`NOVARTIS EXHIBIT 2037
`Par v Novartis, IPR 2016-01479
`Page 4 of 5
`
`
`
`Dated: March 21, 2017
`
`
`
`NOVARTIS EXHIBIT 2037
`Par v Novartis, IPR 2016-01479
`Page 5 of 5
`
`